First-In-Human To Proof-Of-Concept: The DVCR Continuity Model

Transitioning a drug candidate from First-in-Human (FIH) trials through Proof-of-Concept (PoC) is a high-stakes journey where momentum is easily lost. Traditional drug development often suffers from fragmented team handoffs that introduce hidden risks, dilute program knowledge, and stall critical decision-making. Dr. Vince Clinical Research addresses these hurdles through a Continuity Model designed to keep the same high-performing project leadership and clinical teams engaged across the entire early-phase spectrum.

By maintaining a consistent team, sponsors preserve vital program context, including study history, design rationale, and specific regulatory nuances that are often lost during vendor transitions. This integrated approach spans the full study lifecycle—from protocol development and medical monitoring to PK/PD modeling and final CSR. Eliminating the need to "re-learn" a compound or established sponsor preferences allows for streamlined timelines and enhanced deliverable quality. Ultimately, this model fosters deep trust and operational efficiency, ensuring that the move into Phase Ib and Phase II is guided by a team that already understands the data and the expectations.